The investigators purposes are to define the prevalence of omeprazole resistance
gastroesophageal reflux disease (GERD) in systemic sclerosis (SSc), to compare the efficacy
of omeprazole in combination with algycon versus omeprazole in combination with domperidone
on the severity of reflux symptoms in omeprazole resistant GERD in SSc, and to compare the
efficacy of omeprazole in combination with algycon versus omeprazole in combination with
domperidone on the frequency of symptoms in omeprazole- resistant GERD in SSc.